Experience with clindamycin and lactic acid in the treatment of bacterial vaginosis
- Authors: Minakova A.D.1, Dzhibladze T.A.1, Zuev V.M.1, Khokhlova I.D.1, Ageev M.B.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 10, No 4 (2023)
- Pages: 311-316
- Section: Original study articles
- URL: https://journal-vniispk.ru/2313-8726/article/view/219541
- DOI: https://doi.org/10.17816/2313-8726-2023-10-4-311-316
- ID: 219541
Cite item
Abstract
Background. Currently, the search for the most effective methods to treat bacterial vaginosis remains relevant because of the high recurrence rate and resistance of the associated bacteria to antimicrobial drugs, along with the potential side effects of antibiotic therapy. This study aimed to assess the effectiveness and tolerability of using clindamycin and lactic acid sequentially, in comparison to lactic acid monotherapy, for women with bacterial vaginosis.
Materials and methods. An open, randomized, comparative clinical study was conducted with 20 women (aged 18–45 years) who had bacterial vaginosis diagnosed according to R. Amsel criteria. The patients were randomly allocated into two groups, each comprising 10 patients. Group 1 took lactic acid, whereas group 2 employed clindamycin and lactic acid. After 14 days, clinical and laboratory efficacy was assessed based on Amsel criteria.
Results. Objective and subjective symptoms such as vaginal discharge of whitish-gray color with unpleasant odor were not observed in both groups 2 weeks after the end of treatment. Positive dynamics of vaginal pH was recorded in both groups; however, a more pronounced effect was observed in women who used clindamycin and lactic acid.
Conclusions. Both sequential clindamycin and lactic acid monotherapy demonstrated high clinical efficacy and good tolerability. Posttreatment pH values did not differ significantly between the two groups; however, a greater pH deviation was observed in the clindamycin and lactic acid sequential group. Further evaluations of long-term results are necessary.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Alena D. Minakova
I.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: alenami1205@yandex.ru
ORCID iD: 0000-0002-5157-1888
SPIN-code: 6649-7776
Graduate Student
Russian Federation, MoscowTea A. Dzhibladze
I.M. Sechenov First Moscow State Medical University
Email: djiba@bk.ru
ORCID iD: 0000-0003-1540-5628
SPIN-code: 5688-1084
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowVladimir M. Zuev
I.M. Sechenov First Moscow State Medical University
Email: vlzuev@bk.ru
ORCID iD: 0000-0001-8715-2020
SPIN-code: 8725-1419
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowIrina D. Khokhlova
I.M. Sechenov First Moscow State Medical University
Email: irhohlova5@gmail.com
ORCID iD: 0000-0001-8547-6750
SPIN-code: 6858-5235
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, MoscowMikhail B. Ageev
I.M. Sechenov First Moscow State Medical University
Email: mikhaageev@yandex.ru
ORCID iD: 0000-0002-6603-804X
SPIN-code: 3122-7420
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, MoscowReferences
- Coudray MS, Madhivanan P. Bacterial vaginosis ― A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143–148. doi: 10.1016/j.ejogrb.2019.12.035
- Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE. Mixed vaginitis ― more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013;15(2):104–108. doi: 10.1007/s11908-013-0325-5
- Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217–222. doi: 10.1097/olq.0b013e31823e68fe
- Nelson TM, Borgogna JC, Michalek RD, et al. Cigarette smoking is associated with an altered vaginal tract metabolomic profile. Sci Rep. 2018;8(1):852. doi: 10.1038/s41598-017-14943-3
- Amabebe E, Anumba DOC. Mechanistic Insights into Immune Suppression and Evasion in Bacterial Vaginosis. Curr Microbiol. 2022;79(3):84. doi: 10.1007/s00284-022-02771-2
- Machado A, Cerca N. Influence of Biofilm Formation by Gardnerella vaginalis and Other Anaerobes on Bacterial Vaginosis. J Infect Dis. 2015;212(12):1856–1861. doi: 10.1093/infdis/jiv338
- O’Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis. 2011;11:200. doi: 10.1186/1471-2334-11-200
- Haya J, García A, López-Manzanara C, Balawi M, Haya L. Importance of Lactic Acid in Maintaining Vaginal Health: A Review of Vaginitis and Vaginosis Etiopathogenic Bases and a Proposal for a New Treatment. Open J Obstet Gynecol. 2014;4(13):787–799. doi: 10.4236/ojog.2014.413109
- Chawla R, Bhalla P, Chadha S, Grover S, Garget S. Comparison of Hay’s criteria with Nugent’s scoring system for diagnosis of bacterial vaginosis. Biomed Res Int. 2013;2013:365194. doi: 10.1155/2013/365194
- Coleman JS, Gaydos CA. Molecular Diagnosis of Bacterial Vaginosis: an Update. J Clin Microbiol. 2018;56(9):e00342-18. doi: 10.1128/jcm.00342-18
- Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier ShL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190(4):1004–1008. doi: 10.1016/j.ajog.2004.02.015
- Silverberg B, Moyers A, Hinkle T, et al. 2021 CDC Update: Treatment and Complications of Sexually Transmitted Infections (STIs). Venereology. 2022;1(1):23–46. doi: 10.3390/venereology1010004
- Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol. 2000;96(2):256–260. doi: 10.1016/s0029-7844(00)00902-9
- Sobel J, Peipert JF, McGregor JA, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol. 2001;9(1):9–15. doi: 10.1155/s1064744901000035
- Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780
- Faught BM, Reyes S. Characterization and Treatment of Recurrent Bacterial Vaginosis. J Womens Health. 2019;28(9):1218–1226. doi: 10.1089/jwh.2018.7383
- Mendling W, Shazly MAE, Zhang L. The Role of Lactic Acid in the Management of Bacterial Vaginosis: A Systematic Literature Review. Future Pharmacology. 2022;2(3):198–213. doi: 10.3390/futurepharmacol2030014
Supplementary files
